What will Bristol Myers Squibb use Chai Discovery's AI for?

BMS will use Chai's AI models and platform capabilities, including molecular folding and design models, to support the discovery of antibody candidates across its portfolio and to build an AI-powered, continuously learning discovery system.

How does Chai Discovery's AI technology work?

Chai Discovery uses AI to predict and reprogram molecular interactions, helping scientists design new biomolecules with specific properties. The company's models accelerate drug discovery by generating molecules based on defined criteria and compressing discovery cycles.

Is Bristol Myers Squibb the first major pharmaceutical company to partner with Chai Discovery?

No. Pfizer entered a license agreement with Chai Discovery in June to accelerate drug discovery research, making BMS the latest biopharmaceutical company to collaborate with Chai Discovery.

AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIAug 20, 2026Aug 21, 2026, 06:30 JST

Bristol Myers Squibb partners with AI firm Chai for antibody drug discovery

Send on LINE

3 Key Points

What happened
Bristol Myers Squibb (BMS) has partnered with Chai Discovery, an AI company, to use artificial intelligence for discovering therapeutic antibodies. BMS will access Chai's AI models, including molecular folding and design capabilities, to identify antibody candidates across its drug portfolio.
Why it matters
AI is accelerating early-stage drug discovery by compressing development cycles and enabling scientists to target candidates that traditional methods have historically struggled to reach. This collaboration signals that major pharmaceutical companies are rapidly adopting AI platforms to build what BMS calls an 'AI-powered, continuously learning discovery system.' For pharmaceutical and biotech firms, the adoption of such tools may enable faster progression from concept to viable therapeutic candidates.
What to watch
BMS is the latest major pharma partner for Chai Discovery; Pfizer entered a license agreement with Chai Discovery in June to accelerate drug discovery research.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Get news like this every morning, free

Context & Analysis

Chai Discovery's partnership with Bristol Myers Squibb reflects a widening trend in the pharmaceutical industry toward integrating AI into early-stage drug development. The agreement follows Pfizer's license deal with Chai in June, indicating that large-scale biopharmaceutical companies view AI-driven molecular design as a strategic capability. Chai's platform addresses a specific pain point in drug discovery: the ability to target compounds and disease targets that conventional chemistry and screening methods have been unable to reach efficiently. By combining Chai's molecular folding and design models with BMS's deep therapeutic expertise and existing pipeline, the partnership aims to shorten the timeline from initial concept to viable therapeutic candidates—a key measure of success in early drug development where time and capital investment are substantial.

FAQ

What will Bristol Myers Squibb use Chai Discovery's AI for?: BMS will use Chai's AI models and platform capabilities, including molecular folding and design models, to support the discovery of antibody candidates across its portfolio and to build an AI-powered, continuously learning discovery system.
How does Chai Discovery's AI technology work?: Chai Discovery uses AI to predict and reprogram molecular interactions, helping scientists design new biomolecules with specific properties. The company's models accelerate drug discovery by generating molecules based on defined criteria and compressing discovery cycles.
Is Bristol Myers Squibb the first major pharmaceutical company to partner with Chai Discovery?: No. Pfizer entered a license agreement with Chai Discovery in June to accelerate drug discovery research, making BMS the latest biopharmaceutical company to collaborate with Chai Discovery.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.